Question 1

What is the FDA discussion paper on generative AI enabled medical devices?

Accepted Answer

The FDA discussion paper explores scientific and regulatory considerations for medical devices that use generative artificial intelligence. It discusses potential approaches to evaluating safety, clinical performance, generalizability, agentic capabilities, foundation model dependencies, and postmarket monitoring. The publication is a discussion paper and request for feedback, not draft or final guidance.

Question 2

Does the FDA have specific regulations for generative AI enabled medical devices?

Accepted Answer

The FDA discussion paper does not establish new regulations or mandatory requirements specifically for generative AI enabled medical devices. It presents regulatory and scientific considerations that may inform future FDA approaches to GenAI enabled medical devices.

Question 3

How does the FDA evaluate generative AI medical devices?

Accepted Answer

The FDA discussion paper explores a potential risk based approach that considers factors such as the degree of device activity and the potential consequences of incorrect outputs. It also discusses competency based evaluation involving safety, clinical proficiency, generalizability, and, where applicable, agentic AI capabilities.

Question 4

What are the main risks of generative AI enabled medical devices?

Accepted Answer

Potential risks can arise from variable outputs, incorrect or misleading information, inappropriate clinical recommendations, limited generalizability, model changes, third party foundation models, cybersecurity vulnerabilities, and autonomous actions. The level of risk depends significantly on the device&#8217;s intended use and the consequences of an incorrect output.

Question 5

What should manufacturers evaluate for GenAI enabled medical devices?

Accepted Answer

Manufacturers should consider the device&#8217;s safety, clinical proficiency, generalizability, intended use, human oversight, system architecture, foundation model dependencies, cybersecurity, change control, and postmarket performance. For agentic systems, evaluation may also need to consider planning, tool use, autonomous actions, and human oversight checkpoints.

Question 6

What is agentic AI in a medical device?

Accepted Answer

Agentic AI refers to GenAI systems capable of performing multi step activities with varying degrees of autonomy. An agentic medical device may plan actions, select or use tools, execute tasks, evaluate results, and continue acting. These capabilities can introduce additional considerations related to autonomy, human oversight, authorization, failure handling, and interaction with other systems or devices.

Question 7

How can manufacturers manage changes to foundation models used in medical devices?

Accepted Answer

Manufacturers may need controls to understand and manage foundation model versions, changes, limitations, performance characteristics, update processes, and validation requirements. The FDA discussion paper also explores potential mechanisms such as contractual controls, technical controls, and Predetermined Change Control Plans.

Question 8

What is a Foundation Model Master File?

Accepted Answer

A Foundation Model Master File is a concept discussed by FDA that could allow foundation model developers to provide relevant information to FDA for potential reference by medical device manufacturers. It would not represent FDA authorization of the foundation model for medical use. The manufacturer of the finished medical device would remain responsible for demonstrating that its device is safe and effective for its intended use.

Question 9

Why is postmarket monitoring important for generative AI medical devices?

Accepted Answer

GenAI device performance can potentially be affected by foundation model updates, system changes, data source changes, deployment environments, user populations, and emerging real world use patterns. Risk proportionate postmarket monitoring can therefore help manufacturers identify performance degradation, emerging failure modes, subgroup performance issues, and changes requiring further evaluation.

Question 10

Is accuracy enough to demonstrate the performance of a GenAI medical device?

Accepted Answer

No. Accuracy alone may not fully characterize the performance of a GenAI enabled medical device. Depending on the intended use, evaluation may also need to consider safety, clinical proficiency, generalizability, communication of uncertainty, human oversight, and agentic capabilities.

Don’t know where to start with regulations?
Learn from the Experts

Read Our Blogs

Generative AI-Enabled Medical Devices: FDA’s Emerging Regulatory Considerations.

Nanotechnology in Medical Devices – Small Size, Big Regulatory Questions.

Clinical Investigation Plan (CIP) Under EU MDR 2017/745

AI Medical Devices in Europe – One Device, Two Regulations, Double the Headache

Understanding MDR Article 5(5): Health Institution Exemption for In-House Medical Devices

Team-NB’s New MDR Certification Process Guidance: What Medical Device Manufacturers Need to Know

Artificial Intelligence (AI) in Healthcare and Medical Devices

MDR Article 61(10): Using Non-Clinical Data for Clinical Evaluation Under EU MDR

How to Manage Suppliers Under MDSAP: What Auditors Really Expect

IVDR Transition Timeline: What Has Passed and What Still Matters in 2026

Stay Updated

Subscription Successful

CE CERTIFICATION CONSULTANTS FOR MEDICAL DEVICE

CDSCO APPROVALS FOR MEDICAL DEVICES

US FDA 510(k) APPROVAL CONSULTANCY

UKCA CERTIFICATION REGULATORY CONSULTANCY

OTHER REGULATORY CONSULTANCY

Don’t know where to start with regulations?Learn from the Experts